Company intelligence / Profile preview

Immatics

Ownership: Public · IMTX
Employees: ~700
Development stage: Phase 3

Overview

Immatics has multiple clinical programs including IMA901 (Phase 3 for renal cell carcinoma), IMA910 (completed Phase 1/2 for colorectal carcinoma), IMA950 (Phase 1 for brain cancer), and newer programs like IMA101, IMA201, IMA202, IMA203, and IMA301. Recently announced first clinical data on TCER® IMA402 targeting PRAME.

Therapeutic areas: Oncology
Modalities: TCR-T (T cell receptor-engineered T cell)TCR Bispecifics (TCER®)Adoptive Cell Therapies (ACT)Therapeutic Vaccines
Industry: Biotech

Drug pipeline

15 assets

anzutresgene autoleucel

14 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers SquibbGenmabGSKMD Anderson Cancer CenterPfizerCancer Research UK (CRUK)US National Cancer Institute

Financials

Market cap: $1.3B
Total revenue: $9.1M
Enterprise value: $887.3M

Beyond the preview

Go deeper on Immatics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immatics.

Explore the full profile